MCID: PRN014
MIFTS: 52

Paronychia

Categories: Infectious diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Paronychia

MalaCards integrated aliases for Paronychia:

Name: Paronychia 11 75 53 43 14 16
Paronychia Inflammation 11 71
Onychomycosis 71 33
Onychia and Paronychia of Finger 11
Onychia and Paronychia of Toe 11
Fungal Infection of the Nails 33
Fungal Nail Infection 11
Infected Nailfold 11

Classifications:



External Ids:

Disease Ontology 11 DOID:13117
MeSH 43 D010304
NCIt 49 C79702
SNOMED-CT 68 267830000
ICD10 31 L03.0
UMLS 71 C0030578 C0040261

Summaries for Paronychia

Disease Ontology: 11 A nail disease characterized by often-tender bacterial or fungal hand infection or foot infection due to either bacteria or fungus (Candida albicans) where the nail and skin meet at the side or the base of a finger or toe nail. The infection can start suddenly (acute paronychia) or gradually (chronic paronychia). Puss is usually present, along with gradual thickening and browning discoloration of the nail plate.

MalaCards based summary: Paronychia, also known as paronychia inflammation, is related to diarrhea and papillary adenocarcinoma. An important gene associated with Paronychia is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and breast, and related phenotypes are Decreased viability and Decreased viability

Wikipedia: 75 Paronychia is an inflammation of the skin around the nail, which can occur suddenly, when it is usually... more...

Related Diseases for Paronychia

Diseases related to Paronychia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 540)
# Related Disease Score Top Affiliating Genes
1 diarrhea 29.9 GPT ERBB3 ERBB2 EGFR
2 papillary adenocarcinoma 29.8 KRAS HRAS ERBB2
3 lymphangitis 29.8 ERBB2 EGFR ALK
4 bronchus cancer 29.8 ERBB2 EGFR ALK
5 thymus cancer 29.7 MTOR HRAS ERBB2 EGFR
6 neurofibromatosis 29.6 RET KRAS HRAS
7 mantle cell lymphoma 29.6 MTOR ERBB2 EGFR ALK
8 leukemia, chronic lymphocytic 29.4 MTOR KRAS HRAS ERBB2 EGFR ALK
9 papilloma 29.3 KRAS ERBB2 EGFR EGF
10 neurofibromatosis, type i 29.3 RET MTOR KRAS HRAS EGFR
11 sarcoma 29.2 MTOR MAP3K8 KRAS HRAS ALK
12 exanthem 29.0 MTOR KRAS HRAS GPT ERBB2 EGFR
13 skin disease 29.0 MTOR KRAS HRAS GPT ERBB2 EGFR
14 connective tissue disease 28.8 MTOR HRAS GPT ERBB2 EGFR EGF
15 squamous cell carcinoma 28.8 MTOR KRAS HRAS ERBB2 EGFR EGF
16 lung cancer susceptibility 3 28.8 KRAS HRAS ERBB3 ERBB2 EGFR EGF
17 leukemia, acute myeloid 28.5 MTOR KRAS HRAS ERBB2 EGFR EGF
18 peripheral nervous system disease 27.8 RET MTOR KRAS HRAS GPT ERBB2
19 lung cancer 27.3 RET MTOR MAP3K8 KRAS HRAS ERBB4
20 tinea unguium 11.6
21 candidal paronychia 11.2
22 tinea favosa 11.0
23 neuropathy, hereditary sensory and autonomic, type iia 11.0
24 cebpe-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome 11.0
25 immunodeficiency 103 fungal infections 11.0
26 tinea pedis 10.7
27 pyogenic granuloma 10.3
28 tinea capitis 10.3
29 48,xxxy syndrome 10.3
30 48,xxyy syndrome 10.3
31 48,xyyy 10.3
32 dermatomycosis 10.3
33 pemphigus 10.3
34 trachea carcinoma in situ 10.3 KRAS HRAS
35 contact dermatitis 10.3
36 acquired immunodeficiency syndrome 10.3
37 common bile duct neoplasm 10.3 KRAS HRAS
38 hypoganglionosis 10.3 ERBB3 ERBB2
39 ampulla of vater benign neoplasm 10.3 KRAS HRAS
40 bladder urachal carcinoma 10.3 KRAS HRAS
41 hepatic flexure cancer 10.3 KRAS HRAS
42 vaginal carcinosarcoma 10.3 KRAS HRAS
43 urachus cancer 10.3 KRAS HRAS
44 descending colon cancer 10.3 KRAS HRAS
45 mucinous intrahepatic cholangiocarcinoma 10.3 KRAS HRAS
46 breast malignant phyllodes tumor 10.3 ERBB2 EGFR
47 sigmoid neoplasm 10.3 KRAS HRAS
48 appendiceal neoplasm 10.3 KRAS HRAS
49 pancreatic mucinous cystadenoma 10.2 KRAS HRAS
50 transverse colon cancer 10.2 KRAS HRAS

Graphical network of the top 20 diseases related to Paronychia:



Diseases related to Paronychia

Symptoms & Phenotypes for Paronychia

GenomeRNAi Phenotypes related to Paronychia according to GeneCards Suite gene sharing:

25 (show top 50) (show all 55)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.4 HRAS KRAS EGFR MTOR
2 Decreased viability GR00055-A-2 11.4 HRAS KRAS EGFR MTOR
3 Decreased viability GR00055-A-3 11.4 KRAS
4 Decreased viability GR00106-A-0 11.4 ERBB3 KRAS
5 Decreased viability GR00221-A-1 11.4 HRAS KRAS RET EGFR MTOR ALK
6 Decreased viability GR00221-A-2 11.4 HRAS MAP3K8 ERBB3 KRAS RET
7 Decreased viability GR00221-A-3 11.4 ERBB2 HRAS MAP3K8 WNK1
8 Decreased viability GR00221-A-4 11.4 ERBB2 MAP3K8 WNK1 ERBB3 RET EGFR
9 Decreased viability GR00249-S 11.4 WNK1 ALK
10 Decreased viability GR00301-A 11.4 MAP3K8 ERBB3 KRAS RET ERBB4
11 Decreased viability GR00342-S-1 11.4 MAP3K8 MTOR ERBB4
12 Decreased viability GR00342-S-2 11.4 MAP3K8 MTOR
13 Decreased viability GR00342-S-3 11.4 MAP3K8
14 Decreased viability GR00381-A-1 11.4 KRAS
15 Decreased viability GR00386-A-1 11.4 WNK1
16 Decreased viability GR00402-S-2 11.4 MAP3K8 WNK1 RET
17 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.44 MTOR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10.44 ERBB3
19 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.44 KRAS
20 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.44 EGFR
21 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.44 RET
22 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.44 ERBB2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.44 ERBB2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.44 RET
25 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.44 WNK1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.44 ERBB2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.44 EGFR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.44 RET
29 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.44 EGFR
30 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.44 KRAS
31 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.44 RET
32 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.44 ERBB2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.44 EGFR
34 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.44 RET
35 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.44 ERBB3 MTOR ERBB2 RET
36 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.44 KRAS ERBB2
37 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.44 RET
38 Increased shRNA abundance (Z-score > 2) GR00366-A-84 10.44 WNK1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.44 ERBB3 MTOR ERBB2 RET EGFR
40 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.44 ERBB2
41 Increased shRNA abundance (Z-score > 2) GR00366-A-91 10.44 EGFR
42 Decreased substrate adherent cell growth GR00193-A-1 10.01 ERBB3
43 Decreased substrate adherent cell growth GR00193-A-2 10.01 ALK EGFR ERBB3 MAP3K8 MTOR WNK1
44 Decreased substrate adherent cell growth GR00193-A-3 10.01 WNK1
45 Decreased viability with paclitaxel GR00179-A-1 9.83 EGFR MTOR
46 Decreased viability with paclitaxel GR00179-A-2 9.83 MTOR
47 Decreased viability with paclitaxel GR00179-A-3 9.83 EGFR MTOR
48 Increased cell viability after pRB stimulation GR00230-A-1 9.77 EGFR ERBB2 ERBB3 ERBB4 RET
49 Increased cell migration GR00055-A-1 9.76 ERBB4
50 Increased cell migration GR00055-A-3 9.76 ERBB4

MGI Mouse Phenotypes related to Paronychia:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 10.19 ALK EGF EGFR ERBB2 ERBB3 ERBB4
2 nervous system MP:0003631 10.18 ALK EGFR ERBB2 ERBB3 ERBB4 HRAS
3 growth/size/body region MP:0005378 10.17 ALK EGF EGFR ERBB2 ERBB3 HRAS
4 neoplasm MP:0002006 10.11 ALK EGFR ERBB2 ERBB3 HRAS KRAS
5 muscle MP:0005369 10.11 EGFR ERBB2 ERBB3 ERBB4 HRAS KRAS
6 endocrine/exocrine gland MP:0005379 10.1 ALK EGF EGFR ERBB2 ERBB3 ERBB4
7 embryo MP:0005380 9.97 EGFR ERBB2 ERBB3 ERBB4 KRAS MTOR
8 cardiovascular system MP:0005385 9.96 EGFR ERBB2 ERBB3 ERBB4 HRAS KRAS
9 digestive/alimentary MP:0005381 9.92 EGF EGFR ERBB2 ERBB3 HRAS KRAS
10 respiratory system MP:0005388 9.81 ALK EGFR ERBB2 ERBB3 ERBB4 HRAS
11 mortality/aging MP:0010768 9.73 ALK EGFR ERBB2 ERBB3 ERBB4 GINS2
12 integument MP:0010771 9.23 ALK EGF EGFR ERBB2 ERBB3 ERBB4

Drugs & Therapeutics for Paronychia

Drugs for Paronychia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
4
Amorolfine Approved, Investigational Phase 4 78613-35-1
5
Efinaconazole Approved Phase 4 164650-44-6
6
Carbamide peroxide Approved Phase 4 124-43-6
7
Bifonazole Approved, Investigational Phase 4 60628-96-8 2378
8
Amphotericin B Approved, Investigational Phase 4 1397-89-3 5280965
9
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
10
Tavaborole Approved, Investigational Phase 4 174671-46-6 11499245
11 Dermatologic Agents Phase 4
12 Anti-Infective Agents, Local Phase 4
13 Keratolytic Agents Phase 4
14 Pharmaceutical Solutions Phase 4
15 Anti-Infective Agents Phase 4
16 Anti-Bacterial Agents Phase 4
17 Antifungal Agents Phase 4
18 Liposomal amphotericin B Phase 4
19 Protective Agents Phase 4
20 Antiprotozoal Agents Phase 4
21 Antiparasitic Agents Phase 4
22 Antioxidants Phase 4
23 Amebicides Phase 4
24
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
25
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
26
Luliconazole Approved Phase 2, Phase 3 187164-19-8 53394969 3003141
27
Terbinafine Approved, Investigational, Vet_approved Phase 3 91161-71-6 1549008
28
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
29
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
30 Cytochrome P-450 Enzyme Inhibitors Phase 3
31 Cytochrome P-450 CYP3A Inhibitors Phase 3
32 Hormones Phase 3
33 Hormone Antagonists Phase 3
34
Hydroxyitraconazole Phase 3 108222
35 Citrate Phase 3
36
Diclofenac Approved, Vet_approved Phase 2 15307-86-5, 15307-79-6 3033
37
Aminolevulinic acid Approved Phase 2 106-60-5 137
38
Posaconazole Approved, Investigational, Vet_approved Phase 2 171228-49-2 147912
39
Econazole Approved Phase 2 27220-47-9 3198
40
Naftifine Approved Phase 2 65472-88-0 47641
41
Ethanol Approved Phase 2 64-17-5 702
42
Polihexanide Approved, Investigational Phase 2 28757-47-3 20977
43
Albaconazole Investigational Phase 2 187949-02-6 18766909
44 Anti-Inflammatory Agents Phase 2
45 Cyclooxygenase Inhibitors Phase 2
46 Antirheumatic Agents Phase 2
47 Anti-Inflammatory Agents, Non-Steroidal Phase 2
48 Analgesics, Non-Narcotic Phase 2
49 Analgesics Phase 2
50
Ketoconazole Approved, Investigational Phase 1 65277-42-1, 142128-57-2 47576 3823 638701

Interventional clinical trials:

(show top 50) (show all 138)
# Name Status NCT ID Phase Drugs
1 A Multicentre, Randomized, Controlled Study of the Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer Alone for the Treatment of Dermatophytic Onychomycosis (Toenail) Without Matrix Involvement Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
2 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
3 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
4 Change in SCIO (Scoring Clinical Index For Onychomycosis) in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
5 An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
6 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus a Fungal Nail Treatment Set Containing Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
7 A Prospective, Double-blind, Placebo-controlled Trial of Topical Penlac Nail Lacquer for Therapy of Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
8 Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
9 Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study Completed NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
10 A Multicenter, Open Label, Single-arm Study Evaluating the Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis of the Toenails Completed NCT02812771 Phase 4 Efinaconazole
11 Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
12 A Multicenter, Open-label, Non-controlled, Single-arm Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Completed NCT03280927 Phase 4 Jublia®
13 Comparison of the Efficacy and Safety Between Long-pulsed Nd:YAG, Amorolfine and Combination of Long-pulsed Nd:YAG and Amorolfine in Treating Non-dermatophyte and Mixed-infection Onychomycosis Completed NCT02812043 Phase 4 Amorolfine
14 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Completed NCT03110029 Phase 4 Efinaconazole 10% Topical Application Solution [JUBLIA]
15 An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
16 Determination of Antifungal Activity of Loceryl Nail Lacquer 5% When Used Concomitantly With a Cosmetic Nail Varnish Compared to a Loceryl Nail Lacquer (NL) 5% Alone in Treatment of Toenail Distal Subungual Onychomycosis Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
17 Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Unknown status NCT02961634 Phase 3 Ciclopirox 8%
18 A Randomized, Double-blind, Vehicle- and Placebo-Controlled, Multicenter Trial in Patients With Mild to Moderate Distal Subungual Toenail Onychomycosis to Investigate the Efficacy, Tolerability, and Safety of Twice Daily Application of TDT 067 for 48 Weeks Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
19 Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis Unknown status NCT03171584 Phase 3 Terbinafine
20 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
21 A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
22 A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Completed NCT02866032 Phase 3 MOB015B;Ciclopirox 80 mg/g
23 The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01007708 Phase 3 IDP-108;Vehicle
24 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443898 Phase 3 terbinafine;Placebo
25 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443820 Phase 3 terbinafine;Placebo
26 A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Completed NCT02859519 Phase 3 MOB015B;MOB015B Vehicle
27 Multi-Center Trial: Evaluation of PinPointe FootLaser Treatment for Infected Toenails (Onychomycosis) Completed NCT00935649 Phase 2, Phase 3
28 A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail. Completed NCT00356915 Phase 3 Itraconazole 100mg capsules;Itraconazole 200mg tablets;Placebo tablets
29 Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Completed NCT01008033 Phase 3 IDP-108;Vehicle
30 Safety and Efficacy of Luliconazole Solution, 10% With Two Dosing Regimens in Distal Subungual Onychomycosis of the Toenails: A Randomized, Double-Blind, Vehicle-Controlled, Phase 2B/3 Study Completed NCT01431820 Phase 2, Phase 3 Luliconazole Solution, 10%;Vehicle Solution
31 A Double-blind, Randomized, Multicenter, Placebo- Controlled Phase 3 Trial to Prove the Superiority of Bifonazole vs. Placebo After 4 Weeks of Onychomycosis Treatment/ as a Follow-up of a 2 Weeks Treatment of Non-surgical Nail Ablation of Diseased Nail Matrix With 40% Urea Paste Completed NCT00781820 Phase 3 Bifonazole cream 1%;Placebo cream
32 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
33 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
34 Multicentre, Open Label Study to Assess the Tolerability of P-3058 Nail Solution in Paediatric Patients Affected by Mild-to-moderate Onychomycosis Completed NCT02547701 Phase 3 P-3058
35 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Completed NCT02549001 Phase 3 P-3058 10%;vehicle of P-3058 10%;amorolfine 5%
36 Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients Completed NCT03168841 Phase 3 Efinaconazole Topical
37 A Multi-center, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO) Recruiting NCT05279846 Phase 3 MOB015B;Placebo
38 Efficacy of Intralesional Platelet-rich Plasma in Treatment of Onychomycosis: a Randomized Controlled Trial Not yet recruiting NCT05128916 Phase 3 Oral terbinafine
39 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Wks Terminated NCT01208168 Phase 3 NAB001;Vehicle alone
40 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks Terminated NCT01208129 Phase 3 NAB001;Placebo control
41 A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis Withdrawn NCT03094468 Phase 3 P-3058 (terbinafine hydrochloride 10%);Vehicle of P-3058
42 Noveon Laser Treatment of Onychomycosis: A Device Performance Clinical Study Unknown status NCT00771732 Phase 2
43 The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study Unknown status NCT02644551 Phase 2 CELEXT07;Penlac
44 AVALIAÇÃO DO USO DO LASER ERBIUM-DOPED YTTRIUM ALUMINIUM GARNET (Er:YAG) ASSOCIADO AO ESMALTE DE AMOROLFINA NO TRATAMENTO DA ONICOMICOSE Unknown status NCT01528813 Phase 2 Amorolfine lacquer
45 Dr. Bill Antifungal Nail Gel Study Unknown status NCT04341402 Phase 2 Antifungal Nail Gel Study
46 A Multi-center, Randomized, Double-blind, Vehicle-controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients Completed NCT03207906 Phase 2 VBP-926
47 A Randomized, Double Blind, Multiple-site, Placebo-Controlled Study, Comparing the Efficacy and Safety of SUBA™-Itraconazole Capsules Compared to SPORANOX® (Itraconazole) Capsules in the Treatment of Onychomycosis of the Toenail Completed NCT00791219 Phase 2 SUBA-itraconazole;Itraconazole;Placebo
48 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the Efficacy and Safety of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis Completed NCT00730405 Phase 2 Albaconazole 100mg;Albaconazole 200mg;Albaconazole 400mg;Placebo 400 mg
49 A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of ME1111 in Patients With Mild to Moderate Onychomycosis Completed NCT02022215 Phase 2 ME1111 Solution, Low strength;ME1111 Solution, High strength;Matching Vehicle Solution
50 An Unblinded Clinical Trial to Evaluate the Deposition of Terbinafine in the Nail Bed After Iontophoretic Application of ETS Terbinafine Gel in Subjects With Distal Subungual Onychomycosis in the Great Toenail Completed NCT01484145 Phase 2 Terbinafine HCl

Search NIH Clinical Center for Paronychia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ciclopirox
Ciclopirox olamine
Itraconazole
tavaborole
terbinafine
Terbinafine hydrochloride

Cochrane evidence based reviews: paronychia

Genetic Tests for Paronychia

Anatomical Context for Paronychia

Organs/tissues related to Paronychia:

MalaCards : Skin, Lung, Breast, Liver, Bone, Kidney, Bone Marrow

Publications for Paronychia

Articles related to Paronychia:

(show top 50) (show all 4593)
# Title Authors PMID Year
1
[Topical steroids in the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab]. 53 62
20417368 2010
2
Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. 53 62
20103661 2010
3
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. 53 62
19689244 2009
4
[Cutaneous toxicities]. 53 62
18931563 2008
5
Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. 53 62
17147969 2007
6
The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. 53 62
16965448 2006
7
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. 53 62
16844529 2006
8
Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. 53 62
16403122 2006
9
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. 53 62
16012181 2005
10
Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. 53 62
14571080 2003
11
Optimal diagnosis and management of common nail disorders. 62
35238267 2022
12
Poly(pseudo)rotaxanes formed by mixed micelles and α-cyclodextrin enhance terbinafine nail permeation to deeper layers. 62
35602759 2022
13
Prevalence, genetic diversity and antifungal susceptibility profiles of F. fujikuroi, F. solani and Fusarium incarnatum-equiseti species complexes from onychomycosis in north of Iran. 62
35775829 2022
14
Utility of polymerase chain reaction for assessment of onychomycosis during topical therapy. 62
35535809 2022
15
Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach. 62
36198244 2022
16
Tubiechong:A review on ethnomedicinal uses, bioactive chemical constituents and pharmacological activities. 62
35973633 2022
17
Associations between onychomycosis and COVID-19 clinical outcomes: a retrospective cohort study from a US metropolitan center. 62
34773138 2022
18
Onychomycosis in underrepresented groups: an all of us database analysis. 62
36261664 2022
19
Chemotherapy-associated paronychia: don't forget the children. 62
36206933 2022
20
Atypical Presentation of Monkeypox-Virus Infection in a Post-Vaccinated Altered Immunocompetent Patient -A case-report. 62
36219768 2022
21
Fractional CO2 laser - assisted methylene blue photodynamic therapy is a potential alternative therapy for onychomycosis in the era of antifungal resistance. 62
36228978 2022
22
Optimizing Antibiotic Treatment of Skin Infections in Pediatric Emergency and Urgent Care Centers. 62
36073197 2022
23
Strategies for the enhancement of nail plate permeation of drugs to treat onychomycosis. 62
36196052 2022
24
Antifungal nanosuspensions with surfactants and silver for the treatment of onychomycosis. 62
36099971 2022
25
Evaluation of different DNA extraction methods based on steel-bullet beating for molecular diagnosis of onychomycosis. 62
35989493 2022
26
Bacterial nanocellulose patches as a carrier for hydrating formulations to improve the topical treatment of nail diseases. 62
36209980 2022
27
Iontophoresis application for drug delivery in high resistivity membranes: nails and teeth. 62
36209312 2022
28
Current therapeutic insights regarding problematic fingernails and toenails in the Republic of Korea. 62
36153799 2022
29
A descriptive study of onychoscopic features in various subtypes of onychomycosis. 62
36147430 2022
30
Onychomycosis in Patients with Diabetes Mellitus in Africa: A Global Scoping Review, 2000-2021. 62
36057068 2022
31
Effect of Topical Antifungal Luliconazole on Hyphal Morphology of Trichophyton mentagrophytes Grown on in vitro Onychomycosis Model. 62
36057744 2022
32
Nail Clipping with PAS Stain and Correlation with Fungi Isolated in Culture: A Valuable Exchange in the Diagnosis of Onychomycosis. 62
36161087 2022
33
Poor Antifungal Coverage for Onychomycosis in a Cross-Sectional Analysis of Medicaid Formularies. 62
36251605 2022
34
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. 62
36112541 2022
35
Nail Changes in People Living with Human Immunodeficiency Virus: Observational and Cross-Sectional Study in a Third-Level Hospital. 62
36161090 2022
36
S2k guideline: Laser therapy of the skin. 62
36098675 2022
37
Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors. 62
36056941 2022
38
Gefitinib induced Pemphigus Vulgaris with PRIDE complex. 62
35102778 2022
39
Thiamethoxam-Induced Subclinical Onychomadesis. 62
36161079 2022
40
Risk factors for poorly controlled and recurrence-prone ingrown toenails treated with nail braces: A retrospective observational study of 238 cases. 62
34245522 2022
41
Case Study: Soft tissue infection with Raoultella ornithinolytica. 62
35633992 2022
42
Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan. 62
36112905 2022
43
Acute paronychia in a neonate secondary to clindamycin-resistant Staphylococcus aureus. 62
36047838 2022
44
Evaluation of Topical Antifungals Using a New Predictive Animal Model for Efficacy against Severe Tinea Unguium: A Comparison of Efinaconazole and Luliconazole. 62
36094777 2022
45
Systematic review of the prevalence of onychomycosis in children. 62
36130720 2022
46
Factors influencing epidemiology of dermatomycoses at Gdansk, Poland and Grodno, Belarus. 62
36090716 2022
47
A clinical study for the treatment of onychomycosis patients using a novel ROS producing onychomycosis treatment when compared against 5% amorolfine topical lacquer to reduce the visible size of infected toenails. 62
35219908 2022
48
Contact eczema induced by hybrid manicure. The role of acrylates as a causative factor. 62
36090720 2022
49
Reaffirming Adverse Events Related to Lung Cancer Survivors' Target Therapies and Their Apparent Effects on Fear of Cancer Progression, Anxiety, and Depression. 62
36089694 2022
50
Clinical characteristics of ambulatory and hospitalized patients with monkeypox virus infection: an observational cohort study. 62
36028090 2022

Variations for Paronychia

Expression for Paronychia

Search GEO for disease gene expression data for Paronychia.

Pathways for Paronychia

Pathways related to Paronychia according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 WNK1 MTOR MAP3K8 KRAS HRAS ERBB4
2
Show member pathways
13.8 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
3 13.79 RET MTOR KRAS HRAS ERBB4 ERBB3
4
Show member pathways
13.69 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
5
Show member pathways
13.63 ALK EGFR ERBB2 ERBB3 ERBB4 HRAS
6
Show member pathways
13.58 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
7
Show member pathways
13.55 ALK EGF EGFR ERBB2 ERBB3 ERBB4
8
Show member pathways
13.5 MTOR MAP3K8 KRAS HRAS ERBB4 ERBB3
9
Show member pathways
13.4 RET MTOR KRAS HRAS ERBB4 ERBB3
10
Show member pathways
13.4 ALK EGF EGFR ERBB2 ERBB3 ERBB4
11
Show member pathways
13.35 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
12
Show member pathways
13.31 ALK EGF EGFR ERBB2 ERBB3 ERBB4
13
Show member pathways
13.09 MTOR ERBB4 ERBB3 ERBB2 EGFR EGF
14
Show member pathways
13.07 MTOR KRAS HRAS EGFR EGF ALK
15
Show member pathways
13.05 MTOR KRAS HRAS EGFR EGF
16
Show member pathways
12.97 EGF EGFR ERBB4 HRAS KRAS
17
Show member pathways
12.96 ERBB4 ERBB3 ERBB2 EGFR ALK
18
Show member pathways
12.94 MTOR KRAS HRAS EGFR EGF
19
Show member pathways
12.93 EGFR ERBB2 ERBB3 ERBB4 HRAS KRAS
20 12.83 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
21
Show member pathways
12.76 MTOR KRAS HRAS ERBB4 ERBB2 EGFR
22
Show member pathways
12.75 MTOR ERBB4 ERBB3 ERBB2 EGFR EGF
23
Show member pathways
12.71 EGF EGFR HRAS KRAS MAP3K8
24 12.67 MTOR HRAS EGFR EGF
25
Show member pathways
12.66 KRAS HRAS EGFR EGF
26
Show member pathways
12.65 KRAS HRAS EGFR EGF
27
Show member pathways
12.64 MTOR KRAS HRAS EGFR EGF
28
Show member pathways
12.61 MAP3K8 KRAS HRAS EGFR
29
Show member pathways
12.58 KRAS HRAS ERBB2 EGFR
30
Show member pathways
12.54 MTOR KRAS HRAS ERBB2 EGFR EGF
31
Show member pathways
12.52 EGFR ERBB2 ERBB3 ERBB4 HRAS KRAS
32 12.47 MAP3K8 KRAS HRAS EGFR EGF
33
Show member pathways
12.43 KRAS HRAS EGFR EGF
34
Show member pathways
12.43 KRAS HRAS EGFR EGF
35
Show member pathways
12.4 EGF EGFR ERBB2 ERBB3 HRAS
36 12.32 HRAS ERBB2 EGFR EGF
37
Show member pathways
12.28 KRAS HRAS ERBB4 ERBB3 ERBB2 EGFR
38
Show member pathways
12.26 MTOR KRAS HRAS ERBB4 ERBB3 ERBB2
39
Show member pathways
12.22 MTOR HRAS EGFR
40
Show member pathways
12.21 MTOR HRAS ERBB2 EGFR EGF
41 12.19 MTOR KRAS ERBB4 ERBB3 ERBB2 EGFR
42
Show member pathways
12.18 EGF EGFR HRAS KRAS MTOR
43
Show member pathways
12.16 EGF EGFR ERBB2 ERBB3 ERBB4 HRAS
44
Show member pathways
12.15 MTOR MAP3K8 KRAS HRAS ERBB4 ERBB3
45 12.12 RET ERBB4 ERBB3 ERBB2 EGFR EGF
46
Show member pathways
12.08 ERBB4 ERBB3 ERBB2 EGFR
47
Show member pathways
12.07 KRAS HRAS ERBB2 EGFR EGF
48 11.98 HRAS KRAS MAP3K8
49
Show member pathways
11.98 HRAS KRAS MTOR
50
Show member pathways
11.98 KRAS HRAS EGFR EGF

GO Terms for Paronychia

Cellular components related to Paronychia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.32 RET ERBB4 ERBB3 ERBB2 EGFR ALK
2 plasma membrane GO:0005887 10.32 RET ERBB4 ERBB3 ERBB2 EGFR ALK
3 receptor complex GO:0043235 9.93 RET ERBB4 ERBB3 ERBB2 EGFR ALK
4 basal plasma membrane GO:0009925 9.86 EGFR ERBB2 ERBB3 ERBB4
5 ERBB3:ERBB2 complex GO:0038143 9.62 ERBB3 ERBB2
6 plasma membrane region GO:0098590 9.26 ERBB4 ERBB3 ERBB2 EGFR
7 obsolete spanning component of plasma membrane GO:0044214 8.92 ERBB4 ERBB3 ERBB2 EGFR

Biological processes related to Paronychia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.51 ALK EGFR ERBB2 ERBB3 ERBB4 HRAS
2 positive regulation of cell population proliferation GO:0008284 10.37 EGF EGFR ERBB2 ERBB3 ERBB4 HRAS
3 positive regulation of gene expression GO:0010628 10.29 RET MTOR KRAS HRAS ERBB3 ERBB2
4 protein autophosphorylation GO:0046777 10.27 MTOR ERBB4 ERBB2 EGFR ALK
5 positive regulation of MAPK cascade GO:0043410 10.24 RET HRAS ERBB2 EGF ALK
6 protein phosphorylation GO:0006468 10.24 ALK EGFR ERBB2 ERBB3 ERBB4 MAP3K8
7 positive regulation of protein phosphorylation GO:0001934 10.2 MTOR KRAS HRAS ERBB4 ERBB2 EGFR
8 positive regulation of MAP kinase activity GO:0043406 10.19 EGF EGFR ERBB2 HRAS
9 MAPK cascade GO:0000165 10.19 EGFR HRAS KRAS MAP3K8 RET
10 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 10.18 RET ERBB4 ERBB3 ERBB2 EGFR ALK
11 positive regulation of epithelial cell proliferation GO:0050679 10.12 HRAS ERBB2 EGFR EGF
12 neuron apoptotic process GO:0051402 10.1 KRAS HRAS ERBB3
13 epidermal growth factor receptor signaling pathway GO:0007173 10.09 ERBB4 EGFR EGF
14 regulation of cell population proliferation GO:0042127 10.09 ALK EGFR ERBB2 ERBB3 ERBB4 HRAS
15 cellular response to epidermal growth factor stimulus GO:0071364 10.08 ERBB4 ERBB2 EGFR
16 positive regulation of kinase activity GO:0033674 10.03 RET ERBB4 ERBB3 ERBB2 EGFR ALK
17 positive regulation of protein tyrosine kinase activity GO:0061098 9.97 ERBB4 ERBB3 EGFR EGF ALK
18 ERBB2-EGFR signaling pathway GO:0038134 9.95 ERBB2 EGFR EGF
19 ERBB2-ERBB4 signaling pathway GO:0038135 9.91 ERBB4 ERBB2
20 ERBB2-ERBB3 signaling pathway GO:0038133 9.9 ERBB3 ERBB2
21 negative regulation of secretion GO:0051048 9.89 ERBB3 EGF
22 neurogenesis GO:0022008 9.85 ERBB4 ERBB3 ERBB2 EGFR
23 peptidyl-tyrosine phosphorylation GO:0018108 9.73 RET ERBB4 ERBB3 ERBB2 EGFR EGF
24 multicellular organism development GO:0007275 9.63 ALK EGFR ERBB2 ERBB3 ERBB4 RET
25 phosphorylation GO:0016310 9.36 WNK1 RET MTOR MAP3K8 ERBB4 ERBB3

Molecular functions related to Paronychia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 10.39 ALK EGFR ERBB2 ERBB3 ERBB4 MAP3K8
2 protein tyrosine kinase activity GO:0004713 10.1 ALK EGFR ERBB2 ERBB3 ERBB4 RET
3 transferase activity GO:0016740 10.07 WNK1 RET MTOR MAP3K8 GPT ERBB4
4 nucleotide binding GO:0000166 10 WNK1 RET MTOR MAP3K8 KRAS HRAS
5 protein tyrosine kinase activator activity GO:0030296 9.88 ERBB4 ERBB3 EGFR
6 kinase activity GO:0016301 9.85 ALK EGFR ERBB2 ERBB3 ERBB4 MAP3K8
7 ErbB-3 class receptor binding GO:0043125 9.8 ERBB3 ERBB2
8 neuregulin receptor activity GO:0038131 9.78 ERBB4 ERBB3
9 epidermal growth factor receptor activity GO:0005006 9.76 ERBB4 EGFR
10 protein kinase activity GO:0004672 9.7 WNK1 RET MTOR MAP3K8 ERBB4 ERBB3
11 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.36 RET ERBB4 ERBB3 ERBB2 EGFR ALK

Sources for Paronychia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....